(Reuters) – U.S. regulators have accepted an application by Sandoz – the generics arm of Novartis - seeking approval for a copycat version of Amgen’s drug Neupogen, or filgrastim, for patients with low white blood cell counts.
(Reuters) – A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists.
(Reuters) – An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being able to treat it, Danish scientists said on Tuesday.
Last week, Durata Therapeutics, Inc. (Nasdaq:DRTX) announced that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). DALVANCE was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE to its distributors earlier this week.
According to a report that Express Scripts released state legislatures will need to find billions in their budgets to purchase costly new hepatitis C therapy, according to a new state-by-state analysis released today by Express Scripts (NASDAQ: ESRX). But their report is near sighted only looking at the immediate costs of the prescription, instead of the longterm cost stagings this therapy can provide.
Capital efficiency has become a mantra at Atlas, one shared by a number of other early stage biotech investors. It’s a term often repeated in discussions about building young companies, and yet it has become clear that there’s no consistent definition of what the term means.
Biotechs raked in a whopping $1.8 billion in venture cash last quarter, the industry’s biggest haul since PricewaterhouseCoopers and the National Venture Capital Association started keeping track in 1995.
AbbVie Inc. has completed a nearly $55 billion acquisition of drugmaker Shire PLC early Friday morning, the companies announced in a joint statement.
The deal, the largest of a year filled with merger and acquisition activity, will allow AbbVie to move its corporate tax headquarters to Britain, a maneuver that would reduce its tax rate substantially.